Post Profile

New and highly sensitive ELISA technique for bioanalysis of bevacizumab

(Bentham Science Publishers) Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC).
read more


Related Posts

Potential Treatment For Tumors Resistant To VEGF Therapy Offered By Novel Monoclonal Antibody

Health : Medical News Today

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at t...

Preclinical studies involving resistance to antiangiogenic therapies

Academics / Chemistry : EurekAlert: Chemistry

(Bentham Science Publishers) New blood vessel growth, or angiogenesis, is critical for cancer to grow and spread throughout the body. Drugs that target vascular endothelial growth factor -- a key driver of angiogenesis -- are now ap...

Biomarker in Bile VEGF Can Correctly Identify Pancreatic Cancer with High Sensitivity

Health : Newswise Medical News

A marker in bile known as vascular endothelial growth factor (VEGF) plays an important role in the growth of cancerous tumors according to new research presented at the 78th Annual Scientific Meeting of the American College of Gastr...

ULB Identify A New Role Of Vascular Endothelial Growth Factor In Regulating Skin Cancer Stem Cells

Health : Medical News Today

Publication in Nature advanced on line publication: researchers at the Université libre de Bruxelles, ULB, identify a new role of Vascular Endothelial Growth Factor (VEGF) in regulating skin cancer stem cells. One of the key questi...

A specific new ELISA method for analyzing cetuximab

Health : EurekAlert: Health

(Bentham Science Publishers) Cetuximab (CET) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) used for immunotherapy of different types of cancer. This study describes the development and full validatio...


Copyright © 2016 Regator, LLC